Therapeutic Effectiveness and Safety of Mesotherapy in Patients with Osteoarthritis of the Knee

Liang Chen, Dongqing Li, Jun Zhong, Bo Qiu, Xianglei Wu, Liang Chen, Dongqing Li, Jun Zhong, Bo Qiu, Xianglei Wu

Abstract

Objective: To evaluate the therapeutic effectiveness and safety of mesotherapy by comparing it with the classic systematic therapy in patients with osteoarthritis (OA).

Methods: Sixty patients were included and classified into two groups based on the existence of contraindications for nonsteroidal anti-inflammatory drugs (NSAIDs). These patients were treated with oral NSAIDs (Group A) or mesotherapy (Group B). After completing the treatment, the patients were followed up for 6 months. Their clinical features, laboratory results, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were evaluated.

Results: A total of 50 patients completed treatment and follow-up. The patients in Group B had significantly fewer gastric acid-related complaints and requested less supplementary treatment for recurrent pain (p < 0.05). The patients in both groups exhibited decreased blood viscosity after treatment (p < 0.05). WOMAC scores, specifically those for pain and stiffness, were found to be significantly improved after either type of treatment (p < 0.05). Mesotherapy also ameliorated physical function (p < 0.05). Furthermore, Group B presented with better outcomes than Group A (p < 0.05 or p < 0.01).

Conclusion: Our results suggest that mesotherapy is an effective and safe treatment for patients with OA. Clinicians should consider mesotherapy as an alternative therapy for patients with contraindications for NSAID use.

Figures

Figure 1
Figure 1
Injection sites used for mesotherapy. IDP was administered at 6 points along the joint space (4 anterior and 2 posterior). IDS was administered to 4 faces of the knee.
Figure 2
Figure 2
WOMAC evaluations of the patients' clinical outcomes. ∗p < 0.05; ∗∗p < 0.01. WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. This index includes five items for pain (score range: 0–20), two items for stiffness (score range: 0–8), and 17 items for functional limitation (score range: 0–68).

References

    1. Zhang Y., Xu L., Nevitt M. C., et al. Comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and whites in the United States: The Beijing osteoarthritis study. Arthritis & Rheumatism. 2001;44(9):2065–2071. doi: 10.1002/1529-0131(200109)44:9<2065::AID-ART356>;2-Z.
    1. March L. M., Bachmeier C. J. M. Economics of osteoarthritis: A global perspective. Best Practice & Research Clinical Rheumatology. 1997;11(4):817–834. doi: 10.1016/S0950-3579(97)80011-8.
    1. Glyn-Jones S., Palmer A. J., Agricola R., et al. Osteoarthritis. The Lancet. 2015;386(9991):376–387. doi: 10.1016/S0140-6736(14)60802-3.
    1. Kielly J., Davis E. M., Marra C. Practice guidelines for pharmacists: The management of osteoarthritis. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2017;150(3):156–168. doi: 10.1177/1715163517702168.
    1. Machado G. C., Maher C. G., Ferreira P. H., et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: Systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350 doi: 10.1136/bmj.h1225.h1225
    1. Flood J. The role of acetaminophen in the treatment of osteoarthritis. The American Journal of Managed Care. 2010;16:S48–54.
    1. Guyot P., Pandhi S., Nixon R. M., Iqbal A., Chaves R. L., Andrew Moore R. Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. Scandinavian Journal of Pain. 2017;16:74–88. doi: 10.1016/j.sjpain.2017.03.006.
    1. Pistor M. [What is mesotherapy?] Chir Dent Fr. 1976;46(288):59–60.
    1. Mammucari M., Gatti A., Maggiori S., Bartoletti C. A., Sabato A. F. Mesotherapy, definition, rationale and clinical role: a consensus report from the Italian Society of Mesotherapy. European Review for Medical and Pharmacological Sciences. 2011;15(6):682–694.
    1. Mammucari M., Maggiori E., Lazzari M., Natoli S. Should the General Practitioner Consider Mesotherapy (Intradermal Therapy) to Manage Localized Pain? Pain and Therapy. 2016;5(1):123–126. doi: 10.1007/s40122-016-0052-3.
    1. Mammucari M., Gatti A., Maggiori S., Sabato A. F. Role of mesotherapy in musculoskeletal pain: opinions from the Italian Society of Mesotherapy. Evidence-Based Complementary and Alternative Medicine. 2012;2012 doi: 10.1155/2012/436959.436959
    1. Altman R., Asch E., Bloch D. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis & Rheumatology. 1986;29(8):1039–1052. doi: 10.1002/art.1780290816.
    1. Xie F., Li S.-C., Goeree R., et al. Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement. Quality of Life Research. 2008;17(4):595–601. doi: 10.1007/s11136-008-9340-7.
    1. Wei Y., Bai L. Recent advances in the understanding of molecular mechanisms of cartilage degeneration, synovitis and subchondral bone changes in osteoarthritis. Connective Tissue Research. 2016;57(4):245–261. doi: 10.1080/03008207.2016.1177036.
    1. Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005;23(5) supplement 39:109–113.
    1. Hochberg M. C., Altman R. D., April K. T., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care & Research. 2012;64(4):465–474. doi: 10.1002/acr.21596.
    1. Saggini R., Di Stefano A., Dodaj I., Scarcello L., Bellomo R. G. Pes anserine bursitis in symptomatic osteoarthritis patients: A mesotherapy treatment study. The Journal of Alternative and Complementary Medicine. 2015;21(8):480–484. doi: 10.1089/acm.2015.0007.
    1. Costantino C., Marangio E., Coruzzi G. Mesotherapy versus systemic therapy in the treatment of acute low back pain: A randomized trial. Evidence-Based Complementary and Alternative Medicine. 2011;2011:6. doi: 10.1155/2011/317183.317183
    1. Xiao W. H., Bennett G. J. C-fiber spontaneous discharge evoked by chronic inflammation is suppressed by a long-term infusion of lidocaine yielding nanogram per milliliter plasma levels. PAIN. 2008;137(1):218–228. doi: 10.1016/j.pain.2008.02.018.
    1. Sostres C., Gargallo C. J., Arroyo M. T., Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Practice & Research Clinical Gastroenterology. 2010;24(2):121–132. doi: 10.1016/j.bpg.2009.11.005.
    1. Brandt K. D., Bradley J. D. Should the initial drug used to treat osteoarthritis pain be a nonsteroidal antiinflammatory drug? The Journal of Rheumatology. 2001;28(3):467–473.
    1. Lin X., Huang K., Zhu G., Huang Z., Qin A., Fan S. The effects of acupuncture on chronic knee pain due to osteoarthritis: A meta-analysis. Journal of Bone and Joint Surgery - American Volume. 2016;98(18):1578–1585. doi: 10.2106/JBJS.15.00620.
    1. Vas J., Perea-Milla E., Méndez C. Acupuncture and moxibustion as an adjunctive treatment for osteoarthritis of the knee—a large case series. Acupuncture in Medicine. 2004;22(1):23–28. doi: 10.1136/aim.22.1.23.
    1. Mammucari M., Lazzari M., Maggiori E., et al. Role of the informed consent, from mesotherapy to opioid therapy. European Review for Medical and Pharmacological Sciences. 2014;18(4):566–574.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅